Navigation Links
Transdel Pharmaceuticals to Present at Thomas Weisel Partners Healthcare Conference

LA JOLLA, Calif., Sept. 2 /PRNewswire-FirstCall/ -- Transdel Pharmaceuticals, Inc. (OTC Bulletin Board: TDLP) today announced that Dr. Juliet Singh, President and Chief Executive Officer of Transdel, will present a company overview at the Thomas Weisel Partners Healthcare Conference in Boston, MA on Wednesday, September 9, 2009 at 3:15 p.m. EDT.

Interested parties can access a live audio webcast via the Internet by visiting the Investor Relations section of the Company's Web site at

About Transdel Pharmaceuticals, Inc.

Transdel Pharmaceuticals, Inc. (OTCBB: TDLP) is a specialty pharmaceutical company developing non-invasive, topically delivered products. The Company's innovative-patented Transdel(TM) cream formulation technology is designed to facilitate the effective penetration of a variety of products through the tough skin barrier. Ketotransdel(R), the Company's lead late stage pain product, utilizes the Transdel(TM) technology to deliver the active drug, ketoprofen, a non-steroidal anti-inflammatory drug ("NSAID"), through the skin directly into the underlying tissues where the drug exerts its well-known anti-inflammatory and analgesic effects. The Company recently announced that enrollment of patients was completed for the Phase 3 clinical study of Ketotransdel(R) and anticipates releasing the top-line results from the study during the third quarter of 2009. The Company intends to leverage its Transdel(TM) platform technology to expand and create a portfolio of topical products for a variety of indications. The Company is actively pursuing partnerships with companies for Ketotransdel(R) as well to expand its product portfolio for pharmaceutical and cosmetic/cosmeceutical products. For more information, please visit

Safe Harbor Statement

Statements made in this release that are not historical in nature constitute forward-looking statements. Forward-looking statements can be identified by the use of words such as "expects," "plans," "will," "may," "anticipates," "believes," "should," "intends," "estimates," and other words of similar meaning. Please note that forward-looking statements are based on projections, that these projections involve judgment, and that individual judgments may vary. Moreover, these statements are subject to risks and uncertainties that cannot be predicted or quantified and consequently, actual results may differ materially from those expressed or implied by such forward-looking statements. Such risks and uncertainties include, without limitation, risks and uncertainties associated with the uncertainty of the Company's future financial results and its ability to raise additional funds to support its operations, its ability to complete the required clinical trials and obtain FDA approval for Ketotransdel, the efficacy and the commercial success of any cosmetic/cosmeceutical products it develops, the impact of competitive products or pricing, and technological changes. More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is set forth in the Company's filings with the Securities and Exchange Commission, including its Annual Report on Form 10-K and its Quarterly Reports on Form 10-Q filed with the SEC. Such documents may be read free of charge on the SEC's web site at All forward-looking statements included in this release are made as of the date of this press release, and the Company assumes no obligation to update any such forward-looking statements.

SOURCE Transdel Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Transdel Pharmaceuticals Completes Enrollment in Phase 3 Clinical Study for Novel Topical Pain Treatment
2. Transdel Pharmaceuticals Provides Update on Timing of Results for Phase 3 Study
3. Transdel Pharmaceuticals Enters Into License Agreement with JH Direct, LLC for Cosmeceutical Product
4. Transdel Pharmaceuticals, Inc. Featured on National Broadcast Television
5. Transdel Pharmaceuticals, Inc. Retains FLP Pharma to Lead Business Development Activities
6. Transdel Expands Program to Include Cosmetic/Cosmeceutical Products
7. Transdel Pharmaceuticals Appoints Mr. Lynn Swann, Pro-Football Hall of Famer, ABC Sports Broadcaster, and Former Chairman of the Presidents Council on Physical Fitness and Sports, to Board of Directors
8. Transdel Pharmaceuticals to Present at Cowen and Companys 28th Annual Health Care Conference
9. MAP Pharmaceuticals to Present at Upcoming Healthcare and Scientific Conferences
10. Lexicon Pharmaceuticals to Present at the Thomas Weisel Partners Healthcare Conference
11. EPIX Pharmaceuticals, Inc. Announces the P2Y2 Gastrointestinal Early Development Candidate Program Will Be Part of the Intellectual Property Offered For Sale at the September 30, 2009 Auction
Post Your Comments:
(Date:11/24/2015)... ... November 24, 2015 , ... Cancer patients, ... and experiences at a live taping of the next CURE Connections® ... of Gastrointestinal Cancers 2015 Symposium at Georgetown University Hotel & Conference Center in ...
(Date:11/24/2015)... ... November 24, 2015 , ... American Family Care (AFC), the nation’s ... a holiday pop-up clinic located in Metro Atlanta’s North Point Mall. The clinic is ... different way. The location is scheduled to operate through Dec. 24. , Holiday Pop-Up ...
(Date:11/24/2015)... ... 24, 2015 , ... With Thanksgiving right around the corner, holiday travel season ... protect your family and vehicle. , According to the National Highway Traffic Safety Administration, ... is sharing the following safety tips from the NHTSA: , ...
(Date:11/24/2015)... ... ... , LLC launched their Pro Vest, the latest version of their widely popular weight loss ... 10 hours. , The campaign, which will continue to run through Saturday, ... , The PRO Vest provides consumers with a less expensive, one-size fits all comfort option, ...
(Date:11/24/2015)... ... November 24, 2015 , ... Chiropractic student Katie ... (CU-KC), in Overland Park, Kansas. Benson, a fifth-trimester student in the university’s ... Cleveland III on October 16. , “Katie is very excited and greatly appreciative ...
Breaking Medicine News(10 mins):
(Date:11/24/2015)... 24. November 2015 Avery Biomedical ... Systems, ist erfreut, die Berufung von Anders ... geben zu können. ... --> Foto -   ... Von 1984-1986 war er Fellow des Cardiovascular ...
(Date:11/24/2015)... India , November 24, 2015 ... market research report "Spine Biologics Market by Product Type (Bone ... (Anterior Cervical Discectomy and Fusion, Posterior Lumbar Interbody Fusion), End ... MarketsandMarkets, the global market was valued at $1.90 Billion in ... at a CAGR of 4.4% during the forecast period of ...
(Date:11/24/2015)... Nov. 24, 2015 Avery Biomedical Devices (ABD), ... to announce the appointment of Anders Jonzon , ... Dr. Jonzon is a ... Children,s Hospital, Uppsala University, Uppsala and Children,s Hospital, Karolinska, ... was a fellow at the Cardiovascular Institute (UCSF). His ...
Breaking Medicine Technology: